Role for glutathione in the hyposensitivity of LPS-pretreated mice to LPS anorexia

Noemi Hernadfalvi¹, Wolfgang Langhans¹, Claudia von Meyenburg¹, Brigitte Onteniente², Denis Richard³, Denis Arsenijevic¹
¹ Institute of Animal Sciences, ETH Zurich, Schwerzenbach, Switzerland
² INSERM UMR421, Creteil, France
³ Department of Anatomy and Physiology, Laval University, Quebec, Canada

Correspondence: Corresponding author’s current address: Division of Physiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland
<denis.arsenijevic@unifr.ch>

ABSTRACT. To study the role of the redox state regulator glutathione (GSH) in bacterial lipopolysaccharide (LPS)-induced anorexia we measured GSH in liver, serum and brain in response to intraperitoneal (ip) lipopolysaccharide (LPS, 4μg/mouse) injection in LPS-naïve and LPS-pretreated (4μg/mouse) mice. LPS reduced food intake in LPS-naïve mice and LPS pretreatment attenuated this effect. LPS reduced total reduced GSH at 24 hours after injection in LPS-naïve mice. On the other hand, LPS pretreatment caused an upregulation of GSH levels in brain and liver, and this was associated with a significant attenuation of LPS-induced anorexia. In addition, LPS pretreatment increased mitochondrial GSH levels in brain and liver. Pharmacological GSH depletion with diethylmaleate and L-buthionine sulfoximine in LPS-pretreated mice ablated the hyposensitivity to the anorexic effect of LPS. Together, these findings suggest a prominent role for GSH and its intracellular repartition in LPS anorexia.

Keywords: reactive oxygen species, cytokine, food intake, liver, brain, mitochondria

Inflammation, infection and administration of bacterial lipopolysaccharide (LPS) cause oxidative stress, and this entails an increase in tissue concentrations of reactive oxygen species, which are believed to mediate tissue dysfunction and/or destruction. Consequently, antioxidants such as glutathione (GSH) [1] are major determinants of the degree of pathology in models of tissue inflammation [2]. GSH is mainly produced in the liver and controls the redox state in many tissues [3]. GSH has also been supposed to limit LPS-induced pathology [4], but so far it is unknown whether GSH also affects LPS anorexia. GSH can modify cytokine production by several mechanisms [5] and may therefore regulate anorexic cytokine production in response to LPS. Tissue GSH may, in fact, be one determinant of cytokine pathology. Some evidence indicates that, in addition to an increase in total GSH, an increase in mitochondrial GSH is important for its protective effect [6-9]. In this study, we investigated the role of GSH in the food intake response to LPS in LPS-naïve and LPS-pretreated mice. LPS pretreatment normally reduces the pathophysiological responses and the anorexia in response to subsequent LPS administrations, a state often referred to as LPS tolerance [10]. If GSH modulates LPS anorexia, its production and tissue levels in response to LPS may differ between LPS-naïve and LPS-pretreated animals. To examine further a possible causal relationship between GSH and LPS anorexia, we also determined whether pharmacological GSH depletion in LPS-pretreated animals changes the feeding response to LPS, and whether total or mitochondrial GSH levels in brain and liver are indicative of tolerance to LPS-induced anorexia.

METHODS

Mice, housing and diets
We used male, 8-16 week old 25-30g (body weight) c57b6 mice for all experiments. Mice were housed individually in stainless steel cages with a grid floor and kept on a 12:12 hour light:dark cycle. Drug solutions were freshly prepared and always injected 1-2 hours before the onset of the dark cycle. Mice had continuous ad libitum access to water and powdered laboratory diet (Nafag, Gossau, Switzerland). All procedures were approved by the Canton of Zurich Veterinary Office.

Experiment 1: Effects of LPS
Design (table 1) and feeding
LPS from Escherichia coli O111:B4 (L2630, Sigma, Buchs, Switzerland) was dissolved in pyrogen-free saline (Braun, Emmenbrucke, Switzerland) and injected intraperitoneally (ip) at a dose of 4μg/mouse twice, on days 1 and 4 of the experiment, when the animals’ food intake had returned to pre-injection values. Control animals received
an equivalent volume of vehicle. The LPS dose was chosen because it was the lowest dose which caused a reliable food intake reduction for 24 hours in a preliminary experiment in WT mice with 0, 0.4, 4 and 40 µg per 25 g body weight (n = 8/dose). Food intake was measured (± 0.1 g) at 6, 12 and 24 hours after injection by subtracting the weight of the food container and taking into account any spillage. At the end of the experiment, i.e., on day 5, we collected blood, brain and liver to determine total reduced GSH (see below). Each treatment group shown in Table 1 consisted of 7-8 mice.

Glutathione (GSH) in serum, brain and liver
For determination of total reduced GSH, mice were sacrificed with CO2 24 hours after the second injection of LPS or saline. Blood was collected by heart puncture and centrifuged. Serum was kept at -80°C until analysis. Brain and liver were collected, snap frozen in liquid nitrogen, and stored at -80°C until analysis. Throughout the extraction procedure for GSH, samples were kept on ice. Tissues were homogenized using a polytron PT1200 homogenizer (Kinematica, Lucern, Switzerland) with phosphate-buffered saline (600 µl/100 mg tissue). The solution underwent a precipitation reaction with phosphate solution (glacial metaphosphoric acid 1.67 g, disodium EDTA 0.2 g, NaCl 30 g, in 100 ml distilled water). This solution was centrifuged, the supernatant was collected, and phosphate buffer (0.3 M Na2HPO4) added. From this an aliquot was taken and the total reduced GSH tissue levels were measured using a method based on the formation of a chromophoric product resulting from the reaction with 0.04% 5,5-dithiobis-2-nitrobenzoic acid (D8130, DTNB, Sigma Chemicals, St. Louis, MO, USA) and GSH (G4251, Sigma, Buchs, Switzerland) [11].

Mitochondrial GSH in brain and liver
In a separate group of mice, we also examined whether LPS-pretreatment resulted in altered mitochondrial GSH levels in brain and liver. On day, 5 mice (n=4, each) were perfused with ice-cold PBS, brains and livers were removed and mitochondria were isolated as follows [11]: tissues were homogenized in a glass tissue grinder in a solution corresponding to 600 µl (0.25 M sucrose – 1 mM EDTA) per 100 mg of tissue. This suspension was overlayed onto 0.34 M sucrose – 1 mM MgCl₂, and 20 mM phosphate buffer (pH 7.4) and centrifuged at 700 g (10 min, 4°C). The resulting supernatant was centrifuged at 5000 g for 15 min at 4°C. The pellet was re-suspended in 40 ml of 0.25 M sucrose – 1 mM EDTA and centrifuged for 10 min at 24,000 g. The resulting pellet was then re-suspended in 3 ml of 0.25 M sucrose and 2 mM EDTA. Mitochondria numbers were estimated using the succinate dehydrogenase (SDH) activity assay from the mitochondrial preparation. Two µl were used to determine activity by the reduction of 200 µl of succinate/nitroblue tetrazolium solution. From the minimal activity of 0.14 optical density (OD)/min, all isolates were normalized. GSH was then determined as described above.

Experiment 2: Effects of GSH depletion on the responses to LPS

Design and feeding response to LPS
To determine whether GSH depletion alters the animals’ feeding response to 4 µg LPS, we inhibited GSH production and, hence, reduced GSH levels by injecting saline or LPS-pretreated mice with diethylmaleate (DEM, D97703, Sigma, Buchs, Switzerland) and L-buthionine sulfoximine (BSO, B2640, Sigma, Buchs, Switzerland) (DEM/BSO = db) at 800 µl/kg body weight sc and 200 mg/kg [12] body weight ip, 2 hours before the second LPS injection on day 4. Preliminary trials showed that at these doses, the combination of both inhibitors reduced GSH in the liver 2 hours after administration. This resulted in the following six treatment groups (n=4, each; first injection/second injection with or without db treatment): 1) saline/saline no

<table>
<thead>
<tr>
<th>LPS injection groups</th>
<th>Day 1</th>
<th>Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>ss</td>
<td>saline</td>
<td>saline</td>
</tr>
<tr>
<td>sl</td>
<td>saline</td>
<td>LPS</td>
</tr>
<tr>
<td>ls</td>
<td>LPS</td>
<td>saline</td>
</tr>
<tr>
<td>ll</td>
<td>LPS</td>
<td>LPS</td>
</tr>
</tbody>
</table>

Table 1
Time lines for treatments and food intake measurements in mice
db (ss[-db]), 2) ss[+db], 3) LPS/LPS no db (ll[-db]), 4) ll[+db], 5) LPS/saline db treatment (ls[+db], and 6) saline/LPS db treatment (sl[+db]). Food intake was measured at 6, 12 and 24 hours after the second LPS injection.

**Serum acute phase protein response to LPS**

To determine whether GSH depletion altered the acute phase protein response, we determined serum proteins by cellulose gel electrophoresis (Paragon SLE gel – Beckman, Nyon, Switzerland). Mice groups (n = 4, each) were defined as ss, ssdb, ls, sl, ll, lldb and lsdb. Mice were sacrificed with CO₂, 24 hours after the second injection of LPS or saline. Serum was collected by heart puncture and stored at -80°C prior to use. Two ml of serum were loaded on a tract and gels were run for 30 minutes in barbital buffer. Gels were then stained with paragon blue and scanned with the Scion Image program. We also determined whether GSH depletion by DEM/BSO altered serum proteins. Total serum proteins levels were determined by the Bradford protein assay (cat. No. 500-0006, Bio-Rad, Reinach, Switzerland).

**Serum tumour necrosis factor-α (TNFα) and interferon-γ (IFNγ) response to LPS**

To determine whether GSH depletion in LPS-pretreated animals altered TNFα and IFNγ serum levels 24h after the second LPS injection, we used serum from the electrophoresis experiment (see above) and analyzed it for TNFα and IFNγ using IFNγ and TNFα murine ELISA kits from Amersham (Oetilfenilen, Switzerland) [13].

**Statistics**

Differences between groups were determined by using Kruskal-Wallis test with a Dunn post hoc test. A value of p<0.05 was considered significant. Non-parametrical Spearman correlation coefficients were calculated using the Instat program (GraphPad Incorporation, San Diego, CA, USA).

**RESULTS**

**Experiment 1: Effects of LPS**

**Feeding**

Administration of LPS (4 µg/mouse) on day 4 reduced food intake compared to twice saline injected (ss) mice at 6, 12, and 24 hours in LPS naïve mice (sl) (figure 1). LPS-pretreated mice which received a second LPS injection (ll) showed a significant reduction in food intake at 6 and 12 hours compared to saline (ss) controls (figure 1), but this difference did not persist over 24 hours. In addition, ll mice ate more than sl mice at 6, 12 and 24 hours after the second injection (figure 1, n = 8, p < 0.01).

**Serum, brain and liver GSH response to LPS**

LPS reduced serum and brain GSH at 24 hours after the second injection in LPS-naïve mice (sl) compared to twice saline-injected mice (ss) (p < 0.01). LPS-pretreated mice, however, responded to a second LPS injection (ll) with a significant increase in serum and brain GSH compared to their saline-injected controls (p < 0.001) (figure 2). In addition, ls mice had higher GSH levels in liver than saline controls (ss) (p < 0.001) (figure 2).

**Mitochondrial GSH in brain and liver**

Mitochondrial GSH levels were significantly increased in brains and livers of LPS-pretreated mice compared to their corresponding controls (figure 3).

**Experiment 2: Effects of GSH depletion on the responses to LPS**

**Feeding response to LPS**

In Experiment 2, we confirmed our previous results that LPS injection reduced food intake compared to saline injection in saline-pretreated control mice (ss[-db] versus ss[-db]) at 6, 12 and 24 hours after injection (figure 4).
Again, LPS pretreatment attenuated the effect of LPS at all time points measured (sl[-db] versus ll[-db], p < 0.01) (figure 4, also see figure 1). GSH depletion with DEM/BSO (db) per se (ss[+db] and ls[+db] mice) did not affect food intake compared to saline pretreated mice (ss[-db]) or LPS-pretreated hyposensitive mice (ll[-db]). Yet, DEM/BSO treatment 2 hours prior to the second LPS injection antagonized the development of hyposensitivity to LPS-induced anorexia, i.e., it re-established the anorexia, in ll[+db] mice (figure 4). Ll[+db] mice showed significant anorexia compared to their controls (ll[-db], ss[+db]) at 6 hours and 12 hours (both time points p < 0.01), but the effect did not persist over 24 hours.

Serum acute phase protein response to LPS
GSH depletion per se resulted in no major change in serum protein levels (ss[+db] versus ss[-db]). Similar responses were observed in all groups, with the exception of the ll[+db] group, in which serum protein levels were significantly increased (figure 5A). Serum electrophorograms indicate that this increase in ll[+db] mice was due to a general increase rather than an increase in a specific protein (figure 5B).

Serum TNFα and IFNγ response to LPS
Circulating serum IFNγ levels were increased in mice that received LPS for the first time (sl) and in LPS-pretreated...
Effect on LPS anorexia of GSH depletion by DEM/BSO (db) in mice. LPS-naïve or LPS-pretreated mice received either saline or db and were then given either saline or LPS as described in Methods. After the final injection, food intake was measured at 6, 12 and 24h. Mice receiving LPS for the first time sl-[db] ate less than their controls (ss-[db] or ll-[db] mice) at all time points measured (all p < 0.01). DEM/BSO attenuated the LPS hyposensitivity, i.e., re-established the feeding inhibitory effect of LPS at 6 and 12 h in mice (ll+[db] versus ll+[db] or ss+[db] mice, p<0.01). n=4 animals in all groups. *=p < 0.05, **=p < 0.01 compared to ss-[db] mice; b =p < 0.01 compared to ll-[db] mice.

Figure 5

Serum protein levels were similar in all treatment groups at 24h after the second injection, except for ll+[db] mice which had higher serum protein levels than ll+[db] or ss+[db] mice (n = 4, p < 0.001) (5A). In contrast, qualitative changes due to the different treatments were revealed by the electrophoretogram of serum protein (5B), with albumin being the least affected (large band on the left of each electrophoretogram). The location of the gammaglobulin (γ), beta-globulin (β), alpha-1-globulin (α1), alpha-2-globulin (α2) and albumin (Alb) bands are shown in 5B.
animals treated with DEM/BSO (db), whereas LPS-pretreated animals (ll) showed no increase in either cytokine one day after the second LPS treatment (figure 6).

**DISCUSSION**

Consistent with previous findings [14, 15], we report here that ip LPS reduced food intake in LPS-naïve mice, whereas LPS-pretreated mice showed an attenuated anorexia in response to the second LPS injection. Interestingly, this phenomenon was associated with increased glutathione (GSH) levels in brain and liver, raising the possibility that the observed hyposensitivity to the second LPS injection was due to increased tissue GSH levels. Altering antioxidant levels in various animal models has been shown to change the release of cytokines in response to immune challenges. Thus, LPS-induced cytokine production was modified by decreasing or increasing the GSH content with BSO/DEM [18, 19] or N-acetylcysteine [20, 21], respectively. Serum IFNγ levels appeared to be sensitive to GSH changes in LPS-pretreated animals as they were increased 24 h after the second LPS treatment. Our data suggest that LPS has a biphasic effect on tissue GSH levels. Whereas the first LPS injection led to a decrease in serum and brain GSH, presumably because the organism used GSH to cope with the LPS-induced oxidative stress, four days after the first LPS injection, mice had increased liver GSH, perhaps as a result of stimulated hepatic GSH production in response to the initial demand. This additional GSH appeared to be rapidly available when the mice were confronted with the second LPS injection because in this situation they showed higher serum and brain GSH levels when compared to the twice saline-injected control mice. Thus, the stimulated production and rapid distribution of GSH rather than elevated tissue levels of GSH alone may contribute to LPS hyposensitivity. In line with this hypothesis, depletion of GSH rendered LPS-pretreated mice susceptible to LPS anorexia, suggesting that GSH can curb LPS-induced anorexia. Of course, we can also not exclude that a difference in GSH turnover rates between LPS hypo-responsive and LPS-naïve mice contributed to the observed differences in GSH levels because we did not measure GSH turnover. Finally, we also demonstrate that altered intracellular GSH repartitioning occurs in LPS hyposensitivity in both brain and liver. Thus, we observed an increase in mitochondrial GSH in LPS-pretreated mice compared to LPS-naïve mice. In other oxidative stress models, increases in mitochondrial GSH are associated with an increased resistance to the degree of pathology [6-9], and yet other studies have shown that modification of mitochondrial activity can result in resistance to LPS-induced anorexia [21-23]. Further studies using mice with genetically altered mitochondrial GSH levels could be used to critically examine the role of mitochondrial GSH in LPS anorexia by using 1) increased mitochondrial GSH transport [24] in LPS-naïve mice and 2) decreased mitochondrial GSH [25, 26] in LPS tolerance studies. A change in the redox state can alter the immune response due to changes in the production of cytokines and/or acute phase proteins. It has been shown that acute phase proteins, in particular an increase in lipoproteins (found in the beta-globulin faction), can attenuate some of the responses to LPS and their severity [16, 17]. Our electrophoretograms revealed that depletion of GSH _per se_ did not result in a marked, qualitative decrease in the beta-globulins. The lack of major changes between ss[-db] and ss[+db] serum protein levels and the bands at 24 hours after treatment suggests that the difference between ll[-db] and ll[+db] mice was due to specific effects of GSH depletion on the response to LPS. In addition, we can exclude a general liver toxicity effect of db treatment at this time point because albumin levels were not reduced in db treated mice. This suggests that the reduction of GSH by db was not due to general liver toxicity/failure. In summary, these results suggest that LPS affects GSH levels in a tissue-specific manner and that stimulation of GSH production and its rapid distribution in the organism rather than absolute GSH levels confer hyposensitivity to LPS anorexia. The intracellular repartition of GSH may also be
important because hypo-responsive animals had increased mitochondrial GSH and did not display anorexia 24 hours after the second LPS treatment. Further support for a role of GSH in the feeding response to LPS is derived from the fact that mice that are hypo-responsive to the anorexic effect of LPS because of LPS pretreatment can be rendered sensitive again by pharmacological GSH depletion. The generality of this phenomenon, i.e., whether for instance IFNγ-KO mice or other proinflammatory cytokine-deficient mice can also be made more responsive to LPS-induced anorexia by pharmacological GSH depletion remains to be examined.

REFERENCES


